These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 35101037)

  • 1. Is metabolic syndrome a risk factor in hepatectomy? A meta-analysis with subgroup analysis for histologically confirmed hepatic manifestations.
    Murtha-Lemekhova A; Fuchs J; Feiler S; Schulz E; Teroerde M; Kalkum E; Klotz R; Billeter A; Probst P; Hoffmann K
    BMC Med; 2022 Jan; 20(1):47. PubMed ID: 35101037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Serum Bilirubin With Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Liang C; Yu Z; Bai L; Hou W; Tang S; Zhang W; Chen X; Hu Z; Duan Z; Zheng S
    Front Endocrinol (Lausanne); 2022; 13():869579. PubMed ID: 35937795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complex impacts of gallstone disease on metabolic syndrome and nonalcoholic fatty liver disease.
    Lyu J; Lin Q; Fang Z; Xu Z; Liu Z
    Front Endocrinol (Lausanne); 2022; 13():1032557. PubMed ID: 36506064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome and hepatic resection: improving outcome.
    Agrawal S; Daruwala C
    HPB (Oxford); 2011 Dec; 13(12):846-59. PubMed ID: 22081919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: A systematic review and meta-analysis of observational studies.
    Marventano S; Salomone F; Godos J; Pluchinotta F; Del Rio D; Mistretta A; Grosso G
    Clin Nutr; 2016 Dec; 35(6):1269-1281. PubMed ID: 27060021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study.
    Chen YG; Yang CW; Chung CH; Ho CL; Chen WL; Chien WC
    Hepatol Int; 2022 Aug; 16(4):807-816. PubMed ID: 35064545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of cytokines, circulating markers and growth factors on liver regeneration and post-hepatectomy liver failure: a systematic review and meta-analysis.
    Murtha-Lemekhova A; Fuchs J; Ghamarnejad O; Nikdad M; Probst P; Hoffmann K
    Sci Rep; 2021 Jul; 11(1):13739. PubMed ID: 34215781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Metabolic Syndrome on Postoperative Outcomes Among Medicare Beneficiaries Undergoing Hepatectomy.
    Paro A; Tsilimigras DI; Dalmacy D; Mirdad RS; Hyer JM; Pawlik TM
    J Gastrointest Surg; 2021 Oct; 25(10):2545-2552. PubMed ID: 33547584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of non-alcoholic fatty liver and metabolic-associated fatty liver with COVID-19 outcomes: A systematic review and meta-analysis.
    Jagirdhar GSK; Qasba RK; Pattnaik H; Rama K; Banga A; Reddy ST; Flumignan Bucharles AC; Kashyap R; Elmati PR; Bansal V; Bains Y; DaCosta T; Surani S
    World J Gastroenterol; 2023 Jun; 29(21):3362-3378. PubMed ID: 37377589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease (NAFLD), metabolic syndrome and cardiovascular events in atrial fibrillation. A prospective multicenter cohort study.
    Pastori D; Sciacqua A; Marcucci R; Del Ben M; Baratta F; Violi F; Pignatelli P;
    Intern Emerg Med; 2021 Nov; 16(8):2063-2068. PubMed ID: 33713286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of epicardial fat volume and nonalcoholic fatty liver disease with metabolic syndrome: From the CAESAR study.
    Kim BJ; Kim HS; Kang JG; Kim BS; Kang JH
    J Clin Lipidol; 2016; 10(6):1423-1430.e1. PubMed ID: 27919360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response relationship of serum ferritin and dietary iron intake with metabolic syndrome and non-alcoholic fatty liver disease incidence: a systematic review and meta-analysis.
    Yu L; Que T; Zhou Y; Liu Z
    Front Nutr; 2024; 11():1437681. PubMed ID: 39410926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China.
    Yang RX; Zou ZS; Zhong BH; Deng H; He FP; Shi JP; Zhao CY; Mi YQ; Zhou YJ; Di FS; Zheng RD; Du Q; Shang J; Popovic B; Chen J; Fan JG
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):426-432. PubMed ID: 34246549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification.
    Cho YK; Kang YM; Yoo JH; Lee J; Lee SE; Yang DH; Kang JW; Park JY; Jung CH; Kim HK; Lee WJ
    Sci Rep; 2018 Aug; 8(1):12004. PubMed ID: 30104707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic dysfunction-associated fatty liver disease is an early predictor for testosterone deficiency in aging men without metabolic syndrome.
    Liu CC; Huang SP; Lee YC; Lee CH; Huang TY; Geng JH; Chang CW; Lin CY; Juan YS; Wu WJ; Hsieh TJ
    Front Endocrinol (Lausanne); 2023; 14():1252774. PubMed ID: 37854195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benign Prostatic Hyperplasia, Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: Is Metaflammation the Link?
    Russo GI; Cimino S; Castelli T; Favilla V; Gacci M; Carini M; Condorelli RA; La Vignera S; Calogero AE; Motta F; Puzzo L; Caltabiano R; Morgia G
    Prostate; 2016 Dec; 76(16):1528-1535. PubMed ID: 27458062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Souza M; Diaz I; Barchetta I; Mantovani A
    Liver Int; 2024 Jan; 44(1):6-14. PubMed ID: 37833849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Non-Alcoholic Fatty Liver Disease and Metabolic-Associated Fatty Liver Disease with COVID-19-Related Intensive Care Unit Outcomes: A Systematic Review and Meta-Analysis.
    Jagirdhar GSK; Pattnaik H; Banga A; Qasba RK; Rama K; Reddy ST; Bucharles ACF; Kashyap R; Elmati PR; Bansal V; Bains Y; DaCosta T; Surani S
    Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512051
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC.
    Conci S; Cipriani F; Donadon M; Marchitelli I; Ardito F; Famularo S; Perri P; Iaria M; Ansaloni L; Zanello M; La Barba G; Patauner S; Pinotti E; Molfino S; Germani P; Romano M; Sciannamea I; Ferrari C; Manzoni A; Troci A; Fumagalli L; Delvecchio A; Floridi A; Memeo R; Chiarelli M; Crespi M; Zimmitti G; Griseri G; Antonucci A; Zanus G; Tarchi P; Baiocchi GL; Zago M; Frena A; Ercolani G; Jovine E; Maestri M; Valle RD; Grazi GL; Romano F; Giuliante F; Torzilli G; Aldrighetti L; Ruzzenente A;
    Eur J Surg Oncol; 2022 Jan; 48(1):103-112. PubMed ID: 34325939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.